Analysis, modelling and sensing of both physiological and environmental factors for the customized and predictive self-management of Asthma H2020-PHC-2014-single-stage RIA WP7 “Dissemination and exploitation” Overview and plans

Horizon 2020 Communication & Dissemination Requirements New criteria for Communication & Dissemination:  Projects need a comprehensive communication plan  To ensure high visibility of the funded actions  To maximise the results of the impact  New Open Access Policy:  Each beneficiary has to ensure open access to all peer-reviewed scientific publications linked to the project results.  A statement and/or visual means to identify EU funding Without communication, research is not useful, For efforts to have an impact, they need to be known

Partners involved EFA will lead this WP with the support of the following Partner Organisations:  Centre for Research and Technology Hellas (CERTH)  Imperial College London (ICL)  IHP Microelectronics (IHP)  University of Patras (UPAT)  Leiden University Medical Center (LUMC)  Aerocrine AB (AEROCRINE)  University of Mancester (UMAN)  Asthma UK (AUK)  ZorgGemak MedVision360 BV (MV)  Allertec Hellas Pharmaceutical (Allertec)  Cnet Svenska AB (CNET)

Objectives  To raise public awareness of project developments among key user groups, the scientific community and the general public  To facilitate sharing of knowledge inside the Consortium  To develop a business plan for the project outcomes  To manage Intellectual Property Rights

Tasks  T7.1 Dissemination activities, material and publication (Leader: EFA) D7.1; D7.2  T7.2 Exploitation and myAirCoach Business models (Leader: AEROCRINE) D7.3  T7.3 IPR management (Leader: Allertec) D7.4  T7.4 Standardization and concertation actions (Leader: CERTH) D7.5

Deliverables  D7.1 Dissemination Plan and myAirCoach dissemination material (M3, M12, M24, M36, PU, Report)  D7.2 Project Web Presence (Website, Wiki, Blog, Social Media) (M3, PU, Report + Prototype)  D7.3 Exploitation Report and myAirCoach Business models (M24 preliminary, M36 final version, RE, Report)  D7.4 IPR Protection Plan (M12 preliminary, M24 final version, RE, Report)  D7.5 Standardisation and concertation activities report (M24 preliminary, M36 final version, PU, Report)  D7.6 Data Management Plan (M6, updated at M24 and M36, PU, R+s/w)

Milestones and indicators Milestones:  M1: Web site available  M12: Definition of exploitation scenarios. Signature of Exploitation Agreement  M13: Business plan and market analysis available Key success indicators:  Dissemination material, including the web-site, are available. myAirCoach market analysis and business plan highlights the major myAirCoach developments.  Concertation activities with other projects and initiatives with similar objectives have resulted in benefit for all involved parties and new joint initiatives

What to communicate  Objectives, strategic relevance and key facts  News regarding achievements and results  Events promotion and events results  System’s findings that can help and support patients Project outputs to be disseminated:  Ready for use solutions (Vitual community platform, patient guidance platform)  Models, information, lessons learned and recommendations

To whom to communicate  Clinicians  Practitioners in hospitals  Political institutions  Members of EU Commission  Nongovernmental organizations  National and international scientists  Participants of the myAirCoach test campaigns  Researchers and staff involved in myAirCoach  Schools and other educational institutions  General public  Industry, pharmaceutical companies, medical providers Mobile Network operators, SMEs in the medical area, Health service providers

Exploitation  Academic and research organizations:  Direct exploitation by protecting the knowledge created and by granting licenses for its use  Indirect exploitation by increasing the leadership in the respective areas of research  Industrial partners (SMEs):  Direct exploitation of technical developments  Indirect exploitation by leveraging potential business strengths through the association with other partners  End user authorities: through EFA and AUK members

Analysis, modelling and sensing of both physiological and environmental factors for the customized and predictive self-management of Asthma H2020-PHC-2014-single-stage RIA Thank you for your attention! European Federation of Allergy and Airways Diseases Patients' Associations (EFA) EFA 35 Rue du Congrès 1000 Brussels, Belgium 1000 Brussels, Belgium